Biofilm Research Group, Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada.
Microbiology (Reading). 2010 Dec;156(Pt 12):3699-3709. doi: 10.1099/mic.0.040824-0. Epub 2010 Sep 3.
Pseudomonas aeruginosa has long been known to produce phenotypic variants during chronic mucosal surface infections. These variants are thought to be generated to ensure bacterial survival against the diverse challenges in the mucosal environment. Studies have begun to elucidate the mechanisms by which these variants emerge in vitro; however, too little information exists on phenotypic variation in vivo to draw any links between variants generated in vitro and in vivo. Consequently, in this study, the P. aeruginosa gacS gene, which has previously been linked to the generation of small colony variants (SCVs) in vitro, was studied in an in vivo mucosal surface infection model. More specifically, the rat prostate served as a model mucosal surface to test for the appearance of SCVs in vivo following infections with P. aeruginosa gacS(-) strains. As in in vitro studies, deletion of the gacS gene led to SCV production in vivo. The appearance of these in vivo SCVs was important for the sustainability of a chronic infection. In the subset of rats in which P. aeruginosa gacS(-) did not convert to SCVs, clearance of the bacteria took place and healing of the tissue ensued. When comparing the SCVs that arose at the mucosal surface (MS-SCVs) with in vitro SCVs (IV-SCVs) from the same gacS(-) parent, some differences between the phenotypic variants were observed. Whereas both MS-SCVs and IV-SCVs formed dense biofilms, MS-SCVs exhibited a less diverse resistance profile to antimicrobial agents than IV-SCVs. Additionally, MS-SCVs were better suited to initiate an infection in the rat model than IV-SCVs. Together, these observations suggest that phenotypic variation in vivo can be important for maintenance of infection, and that in vivo variants may differ from in vitro variants generated from the same genetic parent.
铜绿假单胞菌在慢性黏膜表面感染期间长期以来一直被认为会产生表型变异。这些变异被认为是为了确保细菌在黏膜环境中的各种挑战中生存而产生的。已经开始研究这些变异在体外出现的机制;然而,关于体内表型变异的信息太少,无法在体外和体内产生的变异之间建立任何联系。因此,在这项研究中,研究了先前与体外小菌落变异(SCV)生成相关的铜绿假单胞菌 gacS 基因在体内黏膜表面感染模型中的作用。更具体地说,大鼠前列腺被用作黏膜表面模型,以测试感染铜绿假单胞菌 gacS(-)株后体内 SCV 的出现。与体外研究一样,gacS 基因的缺失导致体内 SCV 的产生。这些体内 SCV 的出现对于慢性感染的可持续性很重要。在一部分大鼠中,铜绿假单胞菌 gacS(-) 没有转化为 SCV,细菌被清除,组织开始愈合。当比较黏膜表面出现的 SCV(MS-SCVs)与来自同一 gacS(-) 亲本的体外 SCV(IV-SCVs)时,观察到表型变异之间存在一些差异。尽管 MS-SCVs 和 IV-SCVs 都形成了密集的生物膜,但 MS-SCVs 对抗菌药物的耐药谱比 IV-SCVs 更单一。此外,MS-SCVs 比 IV-SCVs 更适合在大鼠模型中引发感染。这些观察结果表明,体内表型变异对于维持感染很重要,并且体内变异可能与来自同一遗传亲本的体外变异不同。